Model-based scenarios for the epidemiology of HIV/AIDS: the consequences of highly active antiretroviral therapy

被引：46

作者：

Dangerfield, BC ^{[1
]}

Fang, YX

Roberts, CA

机构：

[1] Univ Salford, Ctr Operat Res & Appl Stat, Salford M5 4WT, Lancs, England

[2] Univ Salford, Fac Business & Informat, Salford M5 4WT, Lancs, England

来源：

SYSTEM DYNAMICS REVIEW | 2001年 / 17卷 / 02期

关键词：

D O I：

10.1002/sdr.211

中图分类号：

C93 [管理学];

学科分类号：

12 [管理学]; 1201 [管理科学与工程]; 1202 [工商管理学]; 120202 [企业管理];

摘要：

A system dynamics model of HIV/AIDS epidemiology is employed to simulate the effects of triple combination antiretroviral therapy in the treatment of HIV/AIDS. The epidemic data on homosexual men in the UK (1981-1998) have been used to fit the baseline model. The new combination therapies, which supplanted antiviral mono and dual therapy in 1996, are proving to be the most effective prophylaxis yet for halting viral replication in vivo, but many uncertainties still surround their use. A range of model-generated scenarios are created as a means of considering these uncertainties. Possible futures for the HIV/AIDS epidemic are constructed. Copyright (C) 2001 John Wiley & Sons, Ltd.

引用

页码：119 / 150

页数：32

共 32 条

[1]

PRELIMINARY-ANALYSIS OF THE CONCORDE TRIAL [J].

ABOULKER, JP ;

SWART, AM .

LANCET, 1993, 341 (8849) :889-890

[2]

Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral [J].

Andreoni, M ;

Sarmati, L ;

Ercoli, L ;

Nicastri, E ;

Giannini, G ;

Galluzzo, C ;

Pirillo, MF ;

Vella, S .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (07) :555-561

[3]

[Anonymous], 2000, BUSINESS DYNAMICS

[4]

Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997 [J].

Beck, EJ ;

Mandalia, S ;

Williams, I ;

Power, A ;

Newson, R ;

Molesworth, A ;

Barlow, D ;

Easterbrook, P ;

Fisher, M ;

Innes, J ;

Kinghorn, G ;

Mandel, B ;

Pozniak, A ;

Tang, A ;

Tomlinson, D .

AIDS, 1999, 13 (15) :2157-2164

[5]

BLAKESLEE D, 1999, 6 C RETR OPP INF 31

[6]

Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].

Carpenter, CCJ ;

Fischl, MA ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schooley, RT ;

Thompson, MA ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969

[7]

Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel [J].

Carpenter, CCJ ;

Fischl, MA ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schooley, RT ;

Thompson, MA ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02) :146-154

[8]

Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].

Carpenter, CCJ ;

Fischl, MA ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schooley, RT ;

Thompson, MA ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86

[9]

CARPENTER CCJ, 1997, 4 INT C AIDS AS PAC

[10]

COHEN MS, 1998, 5 C RETR OPP INF CHI

← 1 2 3 4 →